Epirubicin Plus Medroxyprogesterone as Second‐Line Treatment of Advanced Prostatic Cancer: A Study by the Italian Trials in Medical Oncology Group
暂无分享,去创建一个
A. Leo | L. Biganzoli | E. Aitini | F. Nolè | E. Bajetta | R. Buzzoni | G. Cornelia | A. Bochicchio | M. D'aprile | E. Veltri | A. D. Lallo | M. Santini | S. Luccarelli | A. R. Bian | A. Lallo
[1] A. Yagoda,et al. Cytotoxic chemotherapy for advanced hormone‐resistant prostate cancer , 1993, Cancer.
[2] F. Daneshgari,et al. Endocrine therapy of advanced carcinoma of the prostate , 1993, Cancer.
[3] N. Geller,et al. Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] W. Bezwoda. Treatment of stage D2 prostatic cancer refractory to or relapsed following castration plus oestrogens. Comparison of aminoglutethimide plus hydrocortisone with medroxyprogesterone acetate plus hydrocortisone. , 1990, British journal of urology.
[5] I. Sasagawa,et al. Effect of high-dose medroxyprogesterone acetate on plasma hormone levels and pain relief in patients with advanced prostatic cancer. , 1990, British journal of urology.
[6] H. Watanabe. [The natural history of prostatic cancer]. , 1989, Gan no rinsho. Japan journal of cancer clinics.
[7] D. Raghavan. Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs. , 1988, Seminars in oncology.
[8] J. Klijn,et al. European Organization for Research and Treatment of Cancer (EORTC) phase II study of low-dose weekly epirubicin in metastatic prostate cancer. , 1987, Cancer treatment reports.
[9] R. Melzack. The McGill Pain Questionnaire: Major properties and scoring methods , 1975, PAIN.
[10] I. Holme,et al. A randomized study on hormone-resistant prostatic cancer: estramustine phosphate versus low dose epirubicin with or without medroxyprogesterone acetate. A Norwegian multicenter study. , 1990, Scandinavian journal of urology and nephrology.
[11] J. Estève,et al. Cancer in the European Community and its member states. , 1990, European journal of cancer.
[12] S. Fosså,et al. Quality of life and treatment of hormone resistant metastatic prostatic cancer , 1990 .
[13] T. Tammela,et al. Sequentially alternating hormone chemotherapy with high-dose medroxy-progesterone acetate and low-dose epirubicin for the treatment of hormone-resistant metastatic prostatic cancer. , 1988, European urology.
[14] B. Ljungberg,et al. Hormonal effects of high dose medroxyprogesterone acetate treatment in males with renal or prostatic adenocarcinoma. , 1988, Scandinavian journal of urology and nephrology.
[15] S. Fosså,et al. High-dose medroxyprogesterone acetate versus prednisolone in hormone-resistant prostatic cancer. A pilot study. , 1985, European Urology.
[16] J. Johansson,et al. High-dose medroxyprogesterone in the treatment of advanced therapy-resistant prostatic carcinoma. , 1985, European urology.
[17] T. Pajak,et al. Adriamycin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity. , 1980, Cancer treatment reports.